Claims

1. AZD1656, or a pharmaceutically acceptable salt thereof, for use in the treatment of pneumonitis and/or myocarditis.

2. AZD1656 for use according to claim 1, wherein the subject of treatment has diabetes, preferably type 1 or type 2 diabetes.

3. AZD1656 for use according to either claim 1 or 2 wherein the subject of treatment is human.

4. AZD1656 for use according to any of claims 1 to 3, wherein the dose of AZD1656 is 1 to 400 mg, preferably 50 mg to 400 mg, preferably 50 mg to 300 mg, most preferably 150 mg to 300 mg.

5. AZD1656 for use according to any preceding claim, wherein administration is by a single daily dose.

6. AZD1656 for use according to claim 5, wherein the single daily dose is 1 to 400 mg, preferably 300 mg to 400 mg.

7. AZD1656 for use according to any of claims 1 to 4, where administration is by a dose twice per day.

8. AZD1656 for use according to claim 7, wherein the dose is 1 to 5 mg or 150 mg to 200 mg.

9. AZD1656 for use according to any one of claims 1 to 7, wherein the dose is 40 to 300 mg.

10. AZD1656 for use according to any one of claims 1 to 7, wherein the lower limit for a dose is 80 mg and the higher limit for a dose is 210 mg.

11. AZD1656 for use according to any preceding claim, to be administered orally.

12. AZD1656 for use according to any of claims 1 to 10, to be administered by parenteral, transdermal, sublingual, rectal or inhaled administration.

13. AZD1656 for use according to any preceding claim, wherein the pneumonitis and/or myocarditis is associated with or caused by a coronavirus infection, such as Covid-19.

14. AZD1556 for use according to any preceding claim, wherein the subject to be treated is infected with, or suspected to be infected with, a coronavirus, such as Covid-19.

15. AZD1556 for use according to any preceding claim, wherein the subject to be treated has long COVID.

16. Use of AZD1656, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of pneumonitis and/or myocarditis.

17. The use of AZD1656, or a pharmaceutically acceptable salt thereof, according to claim 16 having any of the additional features of claims 2 to 15.

18. A method of treating pneumonitis and/or myocarditis comprising administering the patient with AZD1656 or a pharmaceutically acceptable salt thereof.

19. The method according to claim 18 having any of the additional features of claims 2 to 15.